Intervention

Ribociclib 400mg

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting3

Common conditions8

Lead sponsors shown3

Clinical trials

3 shown

Ribociclib for HR-positive HER2-negative Metastatic Breast CancerNCT07164976 · 2025-10-01

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyNCT06953882 · 2025-07-09

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerNCT05216432 · 2021-12-08

Common conditions

Breast Cancer2 Advanced Breast Cancer1 HER2 Negative Breast Cancer1 HER2-negative Breast Cancer1 Metastatic Breast Cancer1 PIK3CA Mutation1 Solid Tumor, Adult1 Unresectable Solid Tumor1

Leading sponsors

Nagoya City University1 Relay Therapeutics, Inc.1 Yale University1

Trial status mix

RECRUITING3

Phase mix

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.